Download PDF
Semin Neurol 2007; 27(1): 022-031
DOI: 10.1055/s-2006-956752
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Mild Cognitive Impairment: Current Research and Clinical Implications

Ronald C. Petersen1
  • 1Alzheimer's Disease Research Center, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota
Further Information

Publication History

Publication Date:
17 January 2007 (online)

    Permissions and Reprints

ABSTRACT

Mild cognitive impairment refers to the transitional state between the cognitive changes of normal aging and the fully developed clinical features of dementia. This topic has received a great deal of attention in the literature in recent years and is being proposed for clinical applications as well. Clinical guidelines, including the original memory-focused criteria and the more recent broadly defined set of criteria, will be presented. The clinical outcome of individuals with mild cognitive impairment will be discussed and several explanations for variability in the literature will be considered. Predictors of progression, including genetic, neuroimaging, biomarker, and clinical characteristics, will be presented, as will the controversies regarding the underlying neuropathology of mild cognitive impairment. The recently completed mild cognitive impairment clinical trials will be discussed and the lessons learned from them translated into recommendations for future investigations. Finally, the clinical utility of mild cognitive impairment, its incorporation into clinical practice, and directions for future research will be proposed.

KEYWORDS

Mild cognitive impairment - memory - Alzheimer's disease

REFERENCES

  • 1 Walker L C, Ibegbu C C, Todd C W et al.. Emerging prospects for the disease-modifying treatment of Alzheimer's disease.  Biochem Pharmacol. 2005;  69 1001-1008
    CrossrefPubMedGoogle Scholar
  • 2 Kral V A. Senescent forgetfulness: benign and malignant.  Can Med Assoc J. 1962;  86 257-260
    PubMedGoogle Scholar
  • 3 Crook T, Bartus R T, Ferris S H et al.. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of a National Institute of Mental Health Work Group.  Dev Neuropsychol. 1986;  2 261-276
    PubMedGoogle Scholar
  • 4 Levy R. Aging-associated cognitive decline.  Int Psychogeriatr. 1994;  6 63-68
    CrossrefPubMedGoogle Scholar
  • 5 LaRue A. Aging and Neuropsychological Assessment. New York; Plenum Press 1992
    Google Scholar
  • 6 Graham J E, Rockwood K, Beattie B L et al.. Prevalence and severity of cognitive impairment with and without dementia in an elderly population.  Lancet. 1997;  349 1793-1796
    CrossrefPubMedGoogle Scholar
  • 7 Fisk J D, Merry H R, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment.  Neurology. 2003;  61 1179-1184
    CrossrefPubMedGoogle Scholar
  • 8 Reisberg B, Ferris S H, de Leon M J, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia.  Am J Psychiatry. 1982;  139 1136-1139
    CrossrefPubMedGoogle Scholar
  • 9 Flicker C, Ferris S H, Reisberg B. A two-year longitudinal study of cognitive function in normal aging and Alzheimer's disease.  J Geriatr Psychiatry Neurol. 1993;  6 84-96
    PubMedGoogle Scholar
  • 10 Kluger A, Ferris S H, Golomb J, Mittelman M S, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly.  J Geriatr Psychiatry Neurol. 1999;  12 168-179
    CrossrefPubMedGoogle Scholar
  • 11 Kluger A, Gianutsos J G, Golomb J et al.. Patterns of motor impairment in normal aging, mild cognitive decline, and early Alzheimer's disease.  J Gerontol B Psychol Sci Soc Sci. 1997;  52 P28-P39
    PubMedGoogle Scholar
  • 12 Kluger A, Gianutsos J G, Golomb J, Ferris S H, Reisberg B. Motor/psychomotor dysfunction in normal aging, mild cognitive decline, and early Alzheimer's disease: diagnostic and differential diagnostic features.  Int Psychogeriatr. 1997;  9(suppl 1) 307-316 , discussion 317-321
    CrossrefPubMedGoogle Scholar
  • 13 Petersen R C, Doody R, Kurz A et al.. Current concepts in mild cognitive impairment.  Arch Neurol. 2001;  58 1985-1992
    CrossrefPubMedGoogle Scholar
  • 14 Petersen R C. Conceptual overview. In: Petersen RC Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York; Oxford University Press 2003: 1-14
    Google Scholar
  • 15 Petersen R C, Smith G E, Waring S C et al.. Mild cognitive impairment: clinical characterization and outcome.  Arch Neurol. 1999;  56 303-308
    CrossrefPubMedGoogle Scholar
  • 16 Ganguli M, Dodge H H, Shen C, DeKosky S T. Mild cognitive impairment, amnestic type: an epidemiologic study.  Neurology. 2004;  63 115-121
    CrossrefPubMedGoogle Scholar
  • 17 Gauthier S, Reisberg B, Zaudig M et al.. Mild cognitive impairment.  Lancet. 2006;  367 1262-1270
    CrossrefPubMedGoogle Scholar
  • 18 Larrieu S, Letenneur L, Orgogozo J M et al.. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort.  Neurology. 2002;  59 1594-1599
    PubMedGoogle Scholar
  • 19 Unverzagt F W, Gao S, Baiyewu O et al.. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging.  Neurology. 2001;  57 1655-1662
    PubMedGoogle Scholar
  • 20 Bennett D A, Wilson R S, Schneider J A et al.. Natural history of mild cognitive impairment in older persons.  Neurology. 2002;  59 198-205
    CrossrefPubMedGoogle Scholar
  • 21 Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status [see comments].  Lancet. 2000;  355 225-228
    CrossrefPubMedGoogle Scholar
  • 22 Winblad B, Palmer K, Kivipelto M et al.. Mild cognitive impairment: beyond controversies, towards a consensus.  J Intern Med. 2004;  256 240-246
    CrossrefPubMedGoogle Scholar
  • 23 Petersen R C. Mild cognitive impairment as a diagnostic entity.  J Intern Med. 2004;  256 183-194
    CrossrefPubMedGoogle Scholar
  • 24 Mueller S G, Weiner M W, Thal L J et al.. The Alzheimer's disease neuroimaging initiative. In: Pettrella JR, Doraiswamy PM Neuroimaging Clinics of North America: Alzheimer's Disease-100 Years of Progress. Philadelphia; Elsevier Saunders 2005: 869-877
    Google Scholar
  • 25 Petersen R C. Clinical evaluation. In: Petersen RC Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York; Oxford University Press 2003: 229-242
    Google Scholar
  • 26 Daly E, Zaitchik D, Copeland M et al.. Predicting conversion to Alzheimer disease using standardized clinical information.  Arch Neurol. 2000;  57 675-680
    CrossrefPubMedGoogle Scholar
  • 27 Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study.  Neurology. 2001;  56 37-42
    CrossrefPubMedGoogle Scholar
  • 28 Aggarwal N T, Wilson R S, Bienias J L, Berry-Kravis E, Bennett D A. The Apolipoprotein E4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.  Neurocase. 2005;  11 3-7
    PubMedGoogle Scholar
  • 29 Petersen R C, Waring S C, Smith G E, Tangalos E G, Thibodeau S N. Predictive value of APOE genotyping in incipient Alzheimer's disease.  Ann NY Acad Sci. 1996;  802 58-69
    CrossrefPubMedGoogle Scholar
  • 30 Petersen R C, Smith G E, Ivnik R J et al.. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.  JAMA. 1995;  273 1274-1278
    CrossrefPubMedGoogle Scholar
  • 31 Petersen R C, Thomas R G, Grundman M et al.. Donepezil and vitamin E in the treatment of mild cognitive impairment.  N Engl J Med. 2005;  352 2379-2388
    CrossrefPubMedGoogle Scholar
  • 32 Dubois B, Albert M L. Amnestic MCI or prodromal Alzheimer's disease?.  Lancet Neurol. 2004;  3 246-248
    PubMedGoogle Scholar
  • 33 Fox N C, Crum W R, Scahill R I et al.. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images.  Lancet. 2001;  358 201-205
    CrossrefPubMedGoogle Scholar
  • 34 Jack Jr C R. Magnetic resonance imaging. In: Petersen RC Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York; Oxford University Press 2003: 105-132
    Google Scholar
  • 35 Killiany R J, Gomez-Isla T, Moss M et al.. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.  Ann Neurol. 2000;  47 430-439
    CrossrefPubMedGoogle Scholar
  • 36 Jack Jr C R, Petersen R C, Xu Y C et al.. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.  Neurology. 1999;  52 1397-1403
    CrossrefPubMedGoogle Scholar
  • 37 Jack Jr C R, Petersen R C, Xu Y et al.. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.  Neurology. 2000;  55 484-489
    PubMedGoogle Scholar
  • 38 Jack Jr C R, Shiung M M, Weigand S D et al.. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.  Neurology. 2005;  65 1227-1231
    CrossrefPubMedGoogle Scholar
  • 39 Reiman E M, Caselli R J, Yun L S et al.. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E.  N Engl J Med. 1996;  334 752-758
    CrossrefPubMedGoogle Scholar
  • 40 Small G W, Mazziotta J C, Collins M T et al.. Apolipoprotein E Type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.  JAMA. 1995;  273 942-947
    CrossrefPubMedGoogle Scholar
  • 41 Drzezga A, Grimmer T, Riemenschneider M et al.. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.  J Nucl Med. 2005;  46 1625-1632
    PubMedGoogle Scholar
  • 42 Klunk W E, Engler H, Nordberg A et al.. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.  Ann Neurol. 2004;  55 306-319
    CrossrefPubMedGoogle Scholar
  • 43 Small W, Kepe V, Ercoli L M et al.. FDDNP-PET binding differentiates MCI from dementia and increases with clinical progression.  Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2006;  2(suppl 1) S318-S319
    PubMedGoogle Scholar
  • 44 Hansson O, Zetterberg H, Buchhave P et al.. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.  Lancet Neurol. 2006;  5 228-234
    CrossrefPubMedGoogle Scholar
  • 45 Markesbery W R, Schmitt F A, Kryscio R J et al.. Neuropathologic substrate of mild cognitive impairment.  Arch Neurol. 2006;  63 38-46
    CrossrefPubMedGoogle Scholar
  • 46 DeKosky S T, Ikonomovic M, Styren S et al.. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortes of elderly subjects with mild cognitive impairment.  Ann Neurol. 2002;  51 145-155
    CrossrefPubMedGoogle Scholar
  • 47 Bennett D A, Schneider J A, Bienias J L, Evans D A, Wilson R S. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.  Neurology. 2005;  64 834-841
    CrossrefPubMedGoogle Scholar
  • 48 Petersen R C, Parisi J E, Dickson D W et al.. Neuropathology of amnestic mild cognitive impairment.  Arch Neurol. 2006;  63 665-672
    CrossrefPubMedGoogle Scholar
  • 49 Jicha G A, Parisi J E, Dickson D W et al.. Neuropathological outcome of mild cognitive impairment following progression to clinical dementia.  Arch Neurol. 2006;  63 674-681
    CrossrefPubMedGoogle Scholar
  • 50 Geda Y E, Petersen R C. Clinical trials in mild cognitive impairment. In: Gauthier S, Cummings JL Alzheimer's Disease and Related Disorders Annual 2001. London; Martin Dunitz 2001: 69-83
    Google Scholar
  • 51 Petersen R C. Mild cognitive impairment clinical trials.  Nat Rev Drug Discov. 2003;  2 646-653
    CrossrefPubMedGoogle Scholar
  • 52 Gauthier S. Pharmacotherapy of mild cognitive impairment.  Dialogues Clin Neurosci. 2004;  6 391-395
    PubMedGoogle Scholar
  • 53 Gold M, Francke S, Nye J S et al.. Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment.  Neurobiol Aging. 2004;  25 S521
    PubMedGoogle Scholar
  • 54 Feldman H, Scheltens P, Scarpini E et al.. Behavioral symptoms in mild cognitive impairment.  Neurology. 2004;  62 1199-1201
    PubMedGoogle Scholar
  • 55 Thal L J, Ferris S H, Kirby L et al.. A randomized, double-blind study of rofecoxib in patients with mild cognitive impairment.  Neuropsychopharmacology. 2005;  30 1204-1215
    CrossrefPubMedGoogle Scholar
  • 56 Lines C R, McCarroll K A, Lipton R B, Block G A. Telephone screening for amnestic mild cognitive impairment.  Neurology. 2003;  60 261-266
    CrossrefPubMedGoogle Scholar
  • 57 Cooper J K, Mungas D, Verma M, Weiler P G. Psychotic symptoms in Alzheimer's disease.  Int J Geriatr Psychiatry. 1991;  6 721-726
    CrossrefPubMedGoogle Scholar
  • 58 Petersen R C, O'Brien J. Mild cognitive impairment should be considered for DSM-V.  J Geriatr Psychiatry Neurol. 2006;  19 147-154
    CrossrefPubMedGoogle Scholar

Ronald C PetersenPh.D. M.D. 

Alzheimer's Disease Research Center, Department of Neurology, Mayo Clinic College of Medicine

200 First Street SW, Rochester, MN 55905